This site is intended for US health care professionals.
01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu
Actor Portrayal
Actor Portrayal

VERQUVO Overview

Add VERQUVO to provide a stabilizing force when your patient needs it most

Dosage & administration

Dosage & administration

Clinical data

Clinical data

Patients’ hearts may never be the same after a HF hospitalization1,2

Patients with WHF face residual risks, whether they are hospitalized or receive outpatient IV diuretics3

~1 in 6 Patients With HFrEF Develops WHF Within an Average of 18 Months of HF Diagnosis; ~56% of Patients With HFrEF Who Develop WHF Are Rehospitalized Within 30 Days of WHF Event; 38.4% of Patients With Worsening Chronic HFrEF 65 Years or Older Die Within 12 Months of a HFH

 

aBased on a retrospective, observational cohort analysis of the PINNACLE registry between January 2011 and December 2014 of 11,064 patients with newly diagnosed HFrEF. Of these patients, 1,851 developed WHF.4

bWHF in this cohort was defined as patients who were free from hospitalization and IV diuretic use for ≥90 days from HFrEF diagnosis and subsequently required IV diuretics or HFH.4

cIn a retrospective, observational cohort analysis of the GWTG-HF. This analysis included 113,348 patients who were hospitalized for worsening chronic HFrEF ≤40% between 2014-2019 and discharged alive, of which 20,387 were aged ≥65 years and linked to Medicare claims.5

GWTG-HF, Get With The Guidelines-Heart Failure; HF, heart failure; HFH, heart failure hospitalization; HFrEF, heart failure with reduced ejection fraction; IV, intravenous; WHF, worsening heart failure.

References:

  1. Gheorghiade M, Marti CN, Sabbah HN, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013;18:123-134.
  2. Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476-2486.
  3. Greene SJ, Bauersachs J, Brugts JJ, et al. Worsening heart failure: nomenclature, epidemiology, and future directions: JACC Review Topic of the Week. J Am Coll Cardiol. 2023;81(4):413-424.
  4. Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection 
 fraction. J Am Coll Cardiol. 2019;73(8):935-944.
  5. Harrington J, Sun JL, Fonarow GC, et al. Clinical profile, health care costs, and outcomes of patients hospitalized for heart failure with severely reduced ejection fraction. J Am Heart Assoc. 2023;12:e028820. doi:10.1161/JAHA.122.028820

Indication

VERQUVO® (vericiguat) tablets 2.5 mg, 5 mg, 10 mg is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

Selected Safety Information

WARNING: EMBRYO-FETAL TOXICITY

Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.

  • VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.
  • VERQUVO is contraindicated in pregnancy.
  • Embryo-Fetal Toxicity: Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.
  • There is a Pregnancy Surveillance Program that monitors pregnancy outcomes in women exposed to VERQUVO during pregnancy. Health care providers should report any prenatal exposure by calling 1-877-888-4231 or at https://pregnancyreporting.verquvo-us.com.
  • In a clinical trial, the most commonly observed adverse events with VERQUVO vs placebo, occurring at a frequency ≥5%, were hypotension (16% vs 15%) and anemia (10% vs 7%).
  • Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.
  • There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.

 

Before prescribing VERQUVO, please read the accompanying Prescribing information including the Boxed Warning about embryo-fetal toxicity. The Medication guide also is available.

Indication

VERQUVO® (vericiguat) tablets 2.5 mg, 5 mg, 10 mg is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

VERQUVO® (vericiguat) tablets 2.5 mg, 5 mg, 10 mg is indicated to reduce the risk

VERQUVO® (vericiguat) tablets 2.5 mg, 5 mg, 10 mg is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.

Selected Safety Information

WARNING: EMBRYO-FETAL TOXICITY

Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.

  • VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.
  • VERQUVO is contraindicated in pregnancy.
  • Embryo-Fetal Toxicity: Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.
  • There is a Pregnancy Surveillance Program that monitors pregnancy outcomes in women exposed to VERQUVO during pregnancy. Health care providers should report any prenatal exposure by calling 1-877-888-4231 or at https://pregnancyreporting.verquvo-us.com.
  • In a clinical trial, the most commonly observed adverse events with VERQUVO vs placebo, occurring at a frequency ≥5%, were hypotension (16% vs 15%) and anemia (10% vs 7%).
  • Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.
  • There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.

 

Before prescribing VERQUVO, please read the accompanying Prescribing information including the Boxed Warning about embryo-fetal toxicity. The Medication guide also is available.

WARNING: EMBRYO-FETAL TOXICITY

Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment

Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.